Using Immunotherapy Combinations in Hepatocellular Carcinoma

Analyses Show Subgroup-Dependent Benefits of Immunotherapy in HCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Renuka Iyer, MD, discussed subgroup analyses of the HIMALAYA trial of frontline durvalumab plus tremelimumab for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.

Comparing IMbrave150 and HIMALAYA Outcomes in Frontline HCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Renuka Iyer, MD, discussed the study designs, patient populations, and efficacy outcomes of the IMbrave150 and HIMALAYA trials of frontline immunotherapy-containing regimens for patients with hepatocellular carcinoma. This is the first of 2 articles based on this event.

Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCC

Milind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.